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BRIEF COMMUNICATIONS 
HYPEREOSINOPHILIC SYNDROME: CAUSE OF PROSTHETIC VALVE OBSTRUCTION 
Saify Arsiwala, MS, MCh, Giles Peek, FRCS, Mike Davies, FRCS, Andrew Sosnoski, MD, and Richard Firmin, FRCS, 
Leicester, England 
In 1975, Chusid and colleagues 1 defined hypereosino- 
philic syndrome as an unexplained eosinophilia lasting 
more than 6 raonths in the presence of end-organ i volve- 
ment. Cardiac involvement occurs in more than 75% of 
patients with the hypereosinophilic syndrome. We report 
a case of prosthetic valve thrombosis caused by eosino- 
philic endocarditis. 
Case report. A 23-year-old girl of Ghanan origin was 
referred to us for mitral regurgitation suspected to be of 
rheumatic origin. She was admitted in an acute condition 
with pulmonary edema, and an urgent mitral valve re- 
placement with a 29 mm St. Jude Medical prosthesis (St. 
Jude Medical, Inc., St. Paul, Minn.) was performed. At 
operation, the gross appearance of the valve suggested a 
rheumatic origin. Incompetence was caused by lack of 
leaflet mobility and was not thought suitable for repair. 
Preoperative chocardiography did not reveal any signif- 
icant findings apart from gross mitral regurgitation. 
On postoperative day 2, she had pyrexia of 38 ° C. Her 
leukocyte count was 41.1 × 106 cells/ml with 81% eosin- 
ophilia. She also had diarrhea. Results of blood cultures, 
urine culture, and stool examination and cultures did not 
suggest any cause. Early morning on day 4, the patient 
became acutely breathless and was transferred to the 
intensive treatment unit. A diagnosis of mitral valve 
prosthetic obstruction was made. She was taken to the 
operating room and cardiopulmonary b pass was quickly 
established. At operation, there was heavy pannus forma- 
tion over a previously placed prosthetic valve. This ob- 
structed both leaflets. The valve was excised and replaced 
with a further 27 mm St. Jude Medical mechanical 
prosthesis. During attempts to wean the patient from 
cardiopulmonary b pass, there was gross right ventricular 
dysfunction. The lungs looked and felt granular and were 
extremely difficult to inflate. Because ours is an active 
extracorporeal membrane oxygenation (ECMO) center, 
the patient was given ECMO. She continued to receive 
ECMO for a period of 10 days. Her eosinophil count 
remained high. Meanwhile, all serologic tests for various 
parasites were done, with negative results. Steroid treat- 
ment were ultimately commenced. Because of bleeding 
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complications and failure to respond to ECMO, ECMO 
was removed, and the patient died on postoperative day 
12. 
Histologic examination f the native valve showed 
thickening of the valve cusp by dense, hyalinized, fibrous 
tissue. There was an increase in small-caliber blood vessels 
within the valve cusp. These vessels contained abundant 
eosinophils. At autopsy, the left ventricle showed apical 
endomyocardial fibrosis and marked fibrosis and thicken- 
ing of the posterior mitral valve anulus. The histologic 
findings in the lungs were grossly masked by the ECMO 
and could not be commented on. The overall finding fits 
well with the diagnosis of eosinophilic endocarditis. 
Discussion. Patients with idiopathic hypereosinophilic 
syndrome have a variety of clinical presentations. The 
most common is a systemic disorder in which cardiac 
disease is one component. High serum levels of eosino- 
philic cationic proteins, with potential hypercoagulable 
effects, contribute to the increased prevalence of throm- 
boembolic episodes among these patients. 
We had diagnostic difficulty with our patient. Hyper- 
eosinophilic syndrome is typically seen in men in their 
fourth decade who live in a temperate climate. Our 
patient was a young girl from a tropical country who had 
symptoms highly suggestive of rheumatic heart disease. 
Eehocardiography did not reveal any evidence of endo- 
myocardial fibrosis. The only positive finding was eosino- 
philia. Mild eosinophilia was recorded once 3 months 
before her operation, when the patient was seen with 
tenosinovitis of her wrist joint. In retrospect, all her 
symptoms could have been caused by eosinophilic endo- 
carditis, as suggested by the histologic haracteristics of
her valve. 
Review of the literature reveals that nine patients o 
date have undergone operation for hypereosinophilic 
syndrome involving the cardiac valves. Eight underwent 
mitral valve replacement and one u derwent annuloplasty 
repair. Most of the authors reported using a xenograft in 
their patients. Harley and coworkers 2 in 1982 used a 
Bj6rk-Shiley valve in their first patient and had to replace 
it as a result of thrombotic obstruction by a porcine 
Hancock valve. Davies and colleagues 3 reported two 
cases, one of which involved mitral valve replacement with 
a Starr-Edwards valve, with no complications. The choice 
of valve prosthesis for this group of patients is difficult. 
Because of the rarity of the disease and the difficulty of 
diagnosis, as in our case, there are no data to evaluate the 
thrombotic potential and long-term structural integrity of 
available prosthetic valves in these patients. Mechanical 
valves are thrombogenic and mural thrombi are charac- 
teristic of hypereosinophilic endocarditis, so it would 
545  
5 4 6 Brief communications 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1995 
appear that a porcine heterograft prosthesis with addi- 
tional anticoagulation would be beneficial. However, the 
toxic effects of eosinophilic granules on the xenograft 
remain to be evaluated. At autopsy in one such patient 
(Harley and colleagues2), although there were no mural 
thrombi, small thrombi were present on the bioprostheses 
despite treatment with warfarin. 
Review of the literature 4 further suggests that the 
exacerbations of symptoms in these patients, as in ours, 
should be treated with prednisolone 1 mg/kg and hydroxy 
urea 500 mg daily. Once the endocarditis  under control 
and remission of systemic symptoms has occurred, oper- 
ation should be planned for relief of cardiac symptoms. 
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A DEHYDROMONOCROTALINE-INDUCED PULMONARY HYPERTENSION MODEL 
IN THE BEAGLE 
Morihito Okada, MD, Chojiro Yamashita, MD, Masayoshi Okada, MD, and Kenji Okada, MD, Kobe, Japan 
Pulmonary hypertension (PH) is a poorly understood 
disease process for which no adequate therapy exists. 
Trials to gain a better understanding of PH have been 
hindered by the lack of relevant animal models. Although 
monocrotaline and hypoxia have both been used to gen- 
erate PH in rats, 1' 2 rats are too small to allow hemody- 
namics to be evaluated accurately. We therefore tried to 
establish a model of PH in a larger animal, the beagle. 
However, a homogeneous model could not be produced 
in dogs by the administration of monocrotaline or by 
the long-term exposure to hypoxia. It is considered that 
monocrotaline is activated to a reactive metabolite in the 
liver and is then transported by red blood cells to the lung, 
where it initiates endothelial injury. The difference re- 
garding the effect of monocrotaline on the lung between a
rat and a dog, which might be due to the hepatic metabolic 
system, encouraged us to examine the reactive hepatic 
metabolites. The purpose of this study was to evaluate the 
cardiopulmonary hemodynamic alterations that devel- 
oped in beagles after the direct administration of dehy- 
dromonocrotaline (DMCT), a putative toxic metabolite of 
monocrotaline, which was made in vitro. 
Twenty purebred beagles with a mean age of 3 months 
and weighing 4 to 6 kg were used for the study. DMCT 
was prepared as described by Mattocks 3and was dissolved 
in dimethylformamide just before injection. After the 
baseline hemodynamics were measured, a single injection 
of DMCT, 1.5 mg/kg (n = 7), 3 mg/kg (n = 10), or 4.5 
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mg/kg (n = 3), was performed. Hemodynamic data and 
blood samples were obtained 8weeks after injection. For 
each hemodynamic measurement, the beagles were anes- 
thetized with sodium pentobarbital (25 mg/kg intrave- 
nously) and permitted to breathe spontaneously. Under 
stable conditions, a Swan-Ganz catheter (Baxter Health- 
care Corporation, Edwards Div., Santa Ana, Calif.) was 
placed from the femoral vein to the pulmonary artery for 
measurement of pressure in the right side of the heart, 
and another catheter was placed in the femoral artery for 
measurement of systemic pressure. So that the weight 
ratio of the right to left ventricle could be calculated, the 
interventricular septum was included with the left ventri- 
cle. Portions of each lung and right ventricle were fixed, 
cut, and stained for histologic study. All animals received 
humane care in compliance with the "Principles of Lab- 
oratory Animal Care" formulated by the National Society 
for Medical Research and the "Guide for the Care and 
Use of Laboratory Animals" prepared by the Institute of 
Laboratory Animal Resources and published by the Na- 
tional Institutes of Health (NIH Publication No. 86-23, 
revised 1985). Data and variables were compared by 
multiple analysis of variance to determine the effect of 
study groups and time points. Differences were considered 
significant atp < 0.05 by the Scheffe F test. All data in the 
text are presented as the mean + the standard eviation. 
Because two beagles receiving 3mg/kg injections and all 
receiving 4.5 mg/kg injections died of acute pulmonary 
edema within the first week of the DMCT administration, 
seven beagles receiving 1.5 mg/kg injections and eight 
receiving 4.5 injections were available for analysis. No 
significant differences were noted between the groups with 
respect to hemodynamic variables at baseline. The systolic 
pulmonary arterial pressure, mean pulmo~aary arterial 
pressure, and pulmonary vascular esistance in beagles 
